Hardean E. Achneck

Hardean E. Achneck, M.D., currently serves as Chief Medical Officer at Aligos Therapeutics, following a role as Senior Vice President and Head of Clinical Development at Pliant Therapeutics. Previously, Hardean held the position of Vice President for Early Stage Clinical Development and Clinical Research at Novo Nordisk Pharmatech A/S. With experience as Director of Medical Affairs and Global Clinical Development at Haemonetics and Chief Medical Officer at Hemostemix, Hardean has a robust background in clinical trial design, medical strategy, and product development. Academic roles at Duke University include Assistant Professor in Surgery and Pathology, where responsibilities spanned research management and the direction of a high-performance lab. Hardean's educational background includes an M.D. from Yale School of Medicine and Executive Education from Harvard Business School, complemented by a Bachelor of Arts in Molecular Biophysics and Biochemistry from Yale University.